Gritstone Oncology Inc
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for tre… Read more
Gritstone Oncology Inc (GRTS) - Net Assets
Latest net assets as of June 2024: $22.19 Million USD
Based on the latest financial reports, Gritstone Oncology Inc (GRTS) has net assets worth $22.19 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($142.54 Million) and total liabilities ($120.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $22.19 Million |
| % of Total Assets | 15.57% |
| Annual Growth Rate | 3.17% |
| 5-Year Change | -61.41% |
| 10-Year Change | N/A |
| Growth Volatility | 59.37 |
Gritstone Oncology Inc - Net Assets Trend (2016–2023)
This chart illustrates how Gritstone Oncology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gritstone Oncology Inc (2016–2023)
The table below shows the annual net assets of Gritstone Oncology Inc from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $51.85 Million | -69.64% |
| 2022-12-31 | $170.78 Million | -20.97% |
| 2021-12-31 | $216.09 Million | +29.60% |
| 2020-12-31 | $166.74 Million | +24.11% |
| 2019-12-31 | $134.34 Million | -9.91% |
| 2018-12-31 | $149.12 Million | +53.29% |
| 2017-12-31 | $97.28 Million | +133.35% |
| 2016-12-31 | $41.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gritstone Oncology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 63931100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $22.00K | 0.04% |
| Other Comprehensive Income | $3.00K | 0.01% |
| Other Components | $711.39 Million | 1372.01% |
| Total Equity | $51.85 Million | 100.00% |
Gritstone Oncology Inc Competitors by Market Cap
The table below lists competitors of Gritstone Oncology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prosper Gold Corp
OTCQX:PGXFF
|
$2.23 Million |
|
ENERAQUA TECH.PLC LS-01
F:Y21
|
$2.23 Million |
|
Mountain Boy Minerals Ltd
OTCQB:MBYMF
|
$2.23 Million |
|
Korporacja Gospodarcza efekt S.A
WAR:EFK
|
$2.24 Million |
|
CASH FINL SVCS NEW HD04
F:CFN
|
$2.23 Million |
|
Jeffs' Brands Ltd
NASDAQ:JFBR
|
$2.23 Million |
|
JSS Real Estate SOCIMI SA
MC:YJSS
|
$2.23 Million |
|
CEKD Bhd
KLSE:0238
|
$2.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gritstone Oncology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 170,781,000 to 51,850,000, a change of -118,931,000 (-69.6%).
- Net loss of 138,490,000 reduced equity.
- Share repurchases of 946,000 reduced equity.
- New share issuances of 67,096,000 increased equity.
- Other comprehensive income increased equity by 83,000.
- Other factors decreased equity by 46,674,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-138.49 Million | -267.1% |
| Share Repurchases | $946.00K | -1.82% |
| Share Issuances | $67.10 Million | +129.4% |
| Other Comprehensive Income | $83.00K | +0.16% |
| Other Changes | $-46.67 Million | -90.02% |
| Total Change | $- | -69.64% |
Book Value vs Market Value Analysis
This analysis compares Gritstone Oncology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $2.08 | $0.02 | x |
| 2017-12-31 | $4.84 | $0.02 | x |
| 2018-12-31 | $16.72 | $0.02 | x |
| 2019-12-31 | $4.00 | $0.02 | x |
| 2020-12-31 | $4.41 | $0.02 | x |
| 2021-12-31 | $2.74 | $0.02 | x |
| 2022-12-31 | $1.88 | $0.02 | x |
| 2023-12-31 | $0.45 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gritstone Oncology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -267.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10404.96%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 3.43x
- Recent ROE (-267.10%) is below the historical average (-78.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -44.98% | 0.00% | 0.00x | 1.11x | $-22.92 Million |
| 2017 | -42.53% | 0.00% | 0.00x | 1.21x | $-51.11 Million |
| 2018 | -43.44% | -5457.03% | 0.01x | 1.27x | $-79.69 Million |
| 2019 | -67.68% | -2083.07% | 0.02x | 1.37x | $-104.36 Million |
| 2020 | -62.74% | -2591.31% | 0.02x | 1.33x | $-121.28 Million |
| 2021 | -34.69% | -160.44% | 0.17x | 1.29x | $-96.56 Million |
| 2022 | -66.24% | -1220.49% | 0.04x | 1.41x | $-130.21 Million |
| 2023 | -267.10% | -10404.96% | 0.01x | 3.43x | $-143.68 Million |
Industry Comparison
This section compares Gritstone Oncology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gritstone Oncology Inc (GRTS) | $22.19 Million | -44.98% | 5.42x | $2.23 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |